References
- Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304. 10.1097/MCG.0b013e31820fb8f621961099
- Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64. 10.1136/gutjnl-2012-302084
- International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240.
- IARC Helicobacter pylori Working Group (2014). Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer IARC Working Group Reports 2014; 8: 1-181.
- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15. 10.1016/S1470-2045(12)70137-722575588
- Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20. 10.1111/j.1523-5378.2009.00738.x20302585
- Tepeš B, Štabuc B. [Slovenian Society for Gastroenterology and Hepatology Guidelines on the management of Helicobacter pylori infection]. Guidelines on the management of Helicobacter pylori infection. [Slovenian]. Zdrav Vestn 2011; 80: 647-56.
- Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67. 10.1136/gutjnl-2015-30925226187502
- Graham DY, Dorea MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti-infe 2016; 14: 577-85. 10.1080/14787210.2016.1178065
- McNicholl AG, Gasbarrini A, Tepeš B, Bordin DS, Lerang F, Leja M, et al. Pan-European registry on H. pylori management (HP-EUREG). Gastroenterology 2016; 150: S875-76. 10.1016/S0016-5085(16)32952-3
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81. 10.1016/j.jbi.2008.08.01018929686
- Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2016; 28: 676-83. 10.1097/MEG.000000000000059026862930
- Tepeš B, Zvezdana O. [Cumulative Helicobacter pylori eradication rates in Slovenia in the year 2008]. [Slovenian]. Zdrav Vestn 2010; 79: 19-24.
- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53. 10.1136/gut.2009.19275720525969
- McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-25. 10.1111/j.1365-2036.2012.05211.x22803691
- Serrano D, Torrado S, Torrado-Santiago S, Gisbert J P. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012; 13: 1303-12. 10.2174/13892001280334139322493986
- Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162. 10.1371/journal.pone.006673023646118
- Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, et al. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One 2014; 9: e105822. 10.1371/journal.pone.010582225141137
- Jeverica S, Tepeš B, Ihan A, Skvarč M. [Primary resistance of Helicobacter pylori]. [Slovenian]. Zdrav Vestn 2010; 79: 25-30.
- Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42. 10.1136/gutjnl-2012-30225422580412
- Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581-9. 10.1111/apt.1306925776067
- McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-9. 10.1136/gutjnl-2013-30482023665990
- Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338-47. 10.3748/wjg.v20.i30.1033825132750
- Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86. 10.1016/j.cgh.2013.05.02823751282
- Rokkas T, Sechopoulos P, Robotis I, MargantinisG, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009; 104: 21-5. 10.1038/ajg.2008.87